Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review.
Lung Cancer
; 142: 120-122, 2020 04.
Article
em En
| MEDLINE
| ID: mdl-32145595
ABSTRACT
OBJECTIVES:
Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) showing longer progression free survival and overall survival than other EGFR-TKI with an improvement in tolerability. MATERIALS ANDMETHODS:
We report about an advanced lung adenocarcinoma patient with severe aplastic anemia during first line osimertinib. RESULTS ANDCONCLUSION:
Severe hematologic toxicity is extremely rare but possible with osimertinib and clinicians should be careful about changes in blood cell count during the use of it.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Acrilamidas
/
Adenocarcinoma de Pulmão
/
Anemia Aplástica
/
Compostos de Anilina
/
Neoplasias Pulmonares
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article